PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
62.82
-0.51 (-0.81%)
At close: Mar 6, 2026, 4:00 PM EST
63.10
+0.28 (0.45%)
After-hours: Mar 6, 2026, 5:57 PM EST
PTC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,731 | 806.78 | 937.82 | 698.8 | 538.59 | Upgrade
|
| Revenue Growth (YoY) | 114.51% | -13.97% | 34.20% | 29.75% | 41.45% | Upgrade
|
| Cost of Revenue | 502.26 | 591.88 | 732.05 | 696.17 | 573.01 | Upgrade
|
| Gross Profit | 1,228 | 214.9 | 205.77 | 2.63 | -34.42 | Upgrade
|
| Selling, General & Admin | 347.14 | 300.91 | 332.54 | 326 | 285.77 | Upgrade
|
| Amortization of Goodwill & Intangibles | 24.74 | 60.74 | 222.64 | 116.55 | 54.75 | Upgrade
|
| Operating Expenses | 371.89 | 361.65 | 555.18 | 442.55 | 340.52 | Upgrade
|
| Operating Income | 856.51 | -146.75 | -349.4 | -439.93 | -374.94 | Upgrade
|
| Interest Expense | -152.23 | -170.39 | -129.18 | -90.87 | -86.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -23.1 | 1.1 | - | -31.3 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -4.68 | 97.02 | 11.81 | -0.62 | -45.19 | Upgrade
|
| EBT Excluding Unusual Items | 676.5 | -219.02 | -466.78 | -562.71 | -506.15 | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.69 | 11.73 | -1.68 | -17.29 | -12.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.1 | -4.4 | - | - | - | Upgrade
|
| Asset Writedown | -1.07 | -163.6 | -217.8 | -33.38 | - | Upgrade
|
| Other Unusual Items | 11.6 | 12.18 | -9.86 | 25.9 | 0.5 | Upgrade
|
| Pretax Income | 696.62 | -363.12 | -696.11 | -587.49 | -518.34 | Upgrade
|
| Income Tax Expense | 13.98 | 0.18 | -69.51 | -28.47 | 5.56 | Upgrade
|
| Net Income | 682.64 | -363.3 | -626.6 | -559.02 | -523.9 | Upgrade
|
| Net Income to Common | 682.64 | -363.3 | -626.6 | -559.02 | -523.9 | Upgrade
|
| Shares Outstanding (Basic) | 80 | 77 | 75 | 72 | 70 | Upgrade
|
| Shares Outstanding (Diluted) | 88 | 77 | 75 | 72 | 70 | Upgrade
|
| Shares Change (YoY) | 14.92% | 2.68% | 4.33% | 1.79% | 6.72% | Upgrade
|
| EPS (Basic) | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 | Upgrade
|
| EPS (Diluted) | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 | Upgrade
|
| Free Cash Flow | 702.34 | -114.19 | -186.86 | -388.67 | -279.55 | Upgrade
|
| Free Cash Flow Per Share | 7.95 | -1.49 | -2.50 | -5.42 | -3.97 | Upgrade
|
| Gross Margin | 70.98% | 26.64% | 21.94% | 0.38% | -6.39% | Upgrade
|
| Operating Margin | 49.49% | -18.19% | -37.26% | -62.95% | -69.62% | Upgrade
|
| Profit Margin | 39.44% | -45.03% | -66.81% | -80.00% | -97.27% | Upgrade
|
| Free Cash Flow Margin | 40.58% | -14.15% | -19.92% | -55.62% | -51.90% | Upgrade
|
| EBITDA | 895.32 | -71.08 | -112.81 | -311.09 | -310.81 | Upgrade
|
| EBITDA Margin | 51.73% | -8.81% | -12.03% | -44.52% | -57.71% | Upgrade
|
| D&A For EBITDA | 38.82 | 75.66 | 236.59 | 128.84 | 64.13 | Upgrade
|
| EBIT | 856.51 | -146.75 | -349.4 | -439.93 | -374.94 | Upgrade
|
| EBIT Margin | 49.49% | -18.19% | -37.26% | -62.95% | -69.62% | Upgrade
|
| Effective Tax Rate | 2.01% | - | - | - | - | Upgrade
|
| Revenue as Reported | 1,731 | 806.78 | 937.82 | 698.8 | 538.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.